The next generation of
cancer diagnostics is here

Introducing miRview® mets2

Rosetta Genomics is pleased to introduce
the next generation of cancer diagnostics: microRNA assays.
miRview® mets2 - a second generation version of miRviewm® mets, featuring an expanded panel of 42 identifiable origins,  and improved classifers
miRview® mets2 is a microRNA-based tests for identifying the origin of metastatic tumors, designed for cancer patients with unknown or uncertain primary origins. The test offers:

  • Accuracy 
  • Efficiency
  • Simple interpretation
  • Routine sample preparation
Download Brochure - miRview® mets²
For additional information, please download brochure